InnovAge (INNV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Oct, 2026Executive summary
Annual meeting scheduled virtually for Dec. 3, 2026; voting covers four Class III directors, say-on-pay frequency, executive compensation, and Deloitte’s FY27 appointment.
Record holders as of Oct. 12, 2026 may vote; 136,456,506 common shares were outstanding, with one vote per share.
Voting matters and shareholder proposals
Board recommends FOR all four director nominees, FOR say-on-pay, and FOR Deloitte; it recommends annual say-on-pay votes.
Director elections require a plurality; say-on-pay and auditor ratification require a majority of votes present and entitled to vote.
Frequency choice receiving the most votes among one, two, or three years will be advisory; the Board and committee will consider the result.
Proposals under SEC Rule 14a-8 for the 2027 annual meeting are due by June 24, 2027; other nominations and proposals are generally due Aug. 5–Sept. 3, 2027.
Board of directors and corporate governance
The Board has 11 directors in three staggered classes; four Class III nominees would serve until the 2029 annual meeting.
Seven directors are independent and four represent principal shareholders; controlled-company status permits reliance on certain Nasdaq governance exemptions.
Chair and CEO roles are separated; the CEO is not a director, while the Chair guides Board strategy and oversight.
Annual evaluations cover Board, committee, and management effectiveness; the Board and committee also review CEO succession and senior-management structure.
Latest events from InnovAge
- Board backs four director nominees, annual say-on-pay voting, compensation approval, and auditor ratification.INNV
Proxy filing - 2027 guidance targets $105–$115 million adjusted EBITDA, reflecting strong growth and margin expansion.INNV
Wells Fargo 21st Annual Healthcare Conference - Strong revenue and margin growth in 2026 set the stage for disciplined, tech-driven expansion in 2027.INNV
Q4 2026 - Revenue up 15.1%, net income positive, strong census growth, FY2026 guidance reaffirmed.INNV
Q1 2026 - Revenue up 11.8%, adjusted EBITDA doubled, and margin expanded; FY26 outlook remains strong.INNV
Q4 2025 - Revenue up 12.4%, net loss halved, and Adjusted EBITDA margin improved to 3.2%.INNV
Q1 2025 - Revenue up 11% to $764M, margins improved, FY25 guidance strong despite regulatory headwinds.INNV
Q4 2024 - Revenue up 13%, adjusted EBITDA rose to $10.8M, but net loss widened on higher costs.INNV
Q3 2025 - Revenue up 10.6% to $209M; FY2025 guidance reaffirmed amid margin and regulatory pressures.INNV
Q2 2025